Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:CUE NASDAQ:GNTA NASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.65-0.9%$1.39$1.05▼$8.74$51.91M1.65753,990 shs207,231 shsCUECue Biopharma$0.72+2.3%$0.80$0.45▼$1.99$55.33M1.58242,796 shs56,184 shsGNTAGenenta Science$2.96+0.5%$3.54$2.56▼$7.28$54.05M0.6215,021 shs2,617 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics+1.84%+9.93%+22.06%+33.87%-77.78%CUECue Biopharma+4.75%-4.85%-14.77%-2.67%+34.35%GNTAGenenta Science+1.71%-2.95%-15.50%-3.70%-15.50%ME23andMe0.00%0.00%0.00%0.00%-92.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.65-0.9%$1.39$1.05▼$8.74$51.91M1.65753,990 shs207,231 shsCUECue Biopharma$0.72+2.3%$0.80$0.45▼$1.99$55.33M1.58242,796 shs56,184 shsGNTAGenenta Science$2.96+0.5%$3.54$2.56▼$7.28$54.05M0.6215,021 shs2,617 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics+1.84%+9.93%+22.06%+33.87%-77.78%CUECue Biopharma+4.75%-4.85%-14.77%-2.67%+34.35%GNTAGenenta Science+1.71%-2.95%-15.50%-3.70%-15.50%ME23andMe0.00%0.00%0.00%0.00%-92.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$15.00811.85% UpsideCUECue Biopharma 0.00N/AN/AN/AGNTAGenenta Science 3.00Buy$25.00746.02% UpsideME23andMe 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ME, GNTA, CUE, and ACRV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACUECue Biopharma$9.29M5.96N/AN/A$0.28 per share2.57GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)CUECue Biopharma-$40.67M-$0.56N/AN/AN/A-469.35%-230.13%-111.16%11/13/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ME, GNTA, CUE, and ACRV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ACRVAcrivon Therapeutics-$0.57-$0.55+$0.02-$0.55N/AN/A8/12/2025Q2 2025CUECue Biopharma-$0.13-$0.09+$0.04-$0.09$2.00 million$2.95 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A10.3110.31CUECue Biopharma0.011.601.60GNTAGenenta ScienceN/A6.896.89ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%CUECue Biopharma35.04%GNTAGenenta Science15.13%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%CUECue Biopharma12.26%GNTAGenenta Science28.99%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.46 million28.78 millionNot OptionableCUECue Biopharma6076.85 million67.43 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableME, GNTA, CUE, and ACRV HeadlinesRecent News About These Companies23andMe Holding Files for Chapter 11 BankruptcySeptember 22 at 5:10 PM | tipranks.comLA firm backs St. Louis-based VeloSource, fueling expansion of medical staffing servicesSeptember 17, 2025 | bizjournals.comBambu Ventures Set to Acquire Telemedicine Pioneer Lemonaid Health Through SPV Amid Chrome Holding Co.'s Bankruptcy ProceedingsSeptember 16, 2025 | hoodline.comH23andMe Bankruptcy Plan Prompts Objection From 30,000 ClaimantsSeptember 15, 2025 | news.bloomberglaw.comN23andMe Offers $3.25 Million Deal for Canadian Data Breach ClassSeptember 12, 2025 | news.bloomberglaw.comN23andMe Seeks Court Approval of $50 Million Data Breach DealSeptember 6, 2025 | news.bloomberglaw.comNThese scientists found Alzheimer's in their genes. Here's what they did nextSeptember 3, 2025 | npr.orgNWhat causes stuttering? It might be in your DNASeptember 3, 2025 | npr.orgNThese scientists found Alzheimer’s in their genes. Here’s what they did nextSeptember 2, 2025 | thepublicsradio.orgTJaylen Brown: "I did my history — my 23andMe. TheyAugust 25, 2025 | msn.comWayne State study says stuttering isn’t your nerves, it’s your genesAugust 24, 2025 | 953mnc.com923andMe Board Approves Changes to CEO’s CompensationAugust 22, 2025 | tipranks.comWhy Ancestry Is the Best DNA Test Kit in 2025August 21, 2025 | cnet.com23andMe Holding Finalizes Asset Sales Amid BankruptcyAugust 19, 2025 | msn.comThe Family Fallout of DNA SurprisesAugust 18, 2025 | newyorker.comNA 1974 murder rocked a small Pittsburgh suburb. Police just found the woman’s killer using a 23andMe-like clueAugust 17, 2025 | yahoo.com23andMe Rebrands to Chrome Holding Co.August 15, 2025 | tipranks.comThey’ve Got Next: The 40 Under 40 - Evan Hill of Cravath, Swaine & MooreAugust 13, 2025 | news.bloomberglaw.comN'I took a DNA test and discovered devastating truth my family hid for 24 years'August 10, 2025 | mirror.co.ukMGenetics of Stuttering: Why It is More Than a Speech DisorderAugust 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Top 5 September Stock Picks: Market Tailwinds Drive New MomentumBy Thomas Hughes | September 1, 2025ME, GNTA, CUE, and ACRV Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.64 -0.02 (-0.90%) As of 12:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Cue Biopharma NASDAQ:CUE$0.72 +0.02 (+2.27%) As of 12:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Genenta Science NASDAQ:GNTA$2.96 +0.02 (+0.51%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
